• Lotus Lake-backed Immunpeutics won China CDE clearance on Aug. 14, 2026 to start trials of IPM514 in lung squamous cancer.
• IPM514 previously cleared trials in esophageal squamous cancer; the company plans a urothelial cancer IND filing in Q1 2027.
• Immunpeutics also has IPM001, a liver-cancer cell therapy, already in clinical-stage studies.
• Separately, Moderna and Merck disclosed on Aug. 19, 2026 that mRNA-4157/V940 with Keytruda met the primary endpoint in INTerpath-001.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lotus Lake Venture Capital Management (Beijing) Co Ltd published the original content used to generate this news brief on August 21, 2026, and is solely responsible for the information contained therein.